A major problem in the antiretroviral treatment of HIV-infections with protease-inhibitors is
the emergence of resistance, resulting from the occurrence of distinct mutations within the …

To understand the basis of drug resistance of the HIV-1 protease, molecular dynamic (MD)
and free energy calculations of the wild-type and three primary resistance mutants, V82F …

Drug resistance is a very important factor contributing to the failure of current HIV therapies.
The ability to understand the resistance mechanism of HIV-protease mutants may be useful …

HIV‐1 protease has been an important drug target for the antiretroviral treatment of HIV
infection. The efficacy of protease drugs is impaired by the rapid emergence of resistant …

The V82F/I84V double mutation is considered as the key residue mutation of the HIV-1
protease drug resistance because it can significantly lower the binding affinity of protease …

Drug resistance of mutations in HIV-1 protease (PR) badly reduce the efficiency of the
current inhibitors in clinical treatments of AIDS. In this work, molecular dynamics (MD) …

A major problem in the antiretroviral treatment of HIV-infections with protease-inhibitors is
the emergence of resistance, resulting from the occurrence of distinct mutations within the …

The protease from type 1 human immunodeficiency virus (HIV‐1) is a critical drug target
against which many therapeutically useful inhibitors have been developed; however, the set …

Human immunodeficiency virus-1 (HIV-1) protease is an important drug target for acquired
immune deficiency syndrome therapy. Nearly 10 small molecule drugs have been approved …

Inhibitors against human immunodeficiency virus type-1 (HIV-1) proteases are finely
effective for anti-HIV-1 treatments. However, the therapeutic efficacy is reduced by the rapid …